Mainz Biomed (MYNZ) announces the commencement of the next phase in its PancAlert project, a research initiative focused on developing a non-invasive blood-based screening test for the early detection of pancreatic cancer. The feasibility phase is intended to confirm the discovery analysis performed in early 2025 in partnership with Liquid Biosciences which demonstrated sensitivity of 95% with specificity of 98% for the detection of pancreatic cancer in blood samples.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting
- Mainz Biomed N.V. Secures $4 Million Through Securities Offering
- Mainz Biomed prices $4.0M offering of common stock at $2.00 per unit
- Mainz Biomed announces interim read out for eAArly DETECT 2 study
- Mainz Biomed files to sell 2.45M ordinary units